{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:53:56Z","timestamp":1784843636765,"version":"3.55.0"},"reference-count":38,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0506402"],"award-info":[{"award-number":["2023ZD0506402"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-049"],"award-info":[{"award-number":["2021-I2M-1-049"]}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with COPD are at an elevated risk of cardiovascular events, particularly following acute exacerbations. Existing prediction models underestimate their risk. We developed and validated the CE-MACE model to predict 1-year major adverse cardiovascular event (MACE) risk following a COPD exacerbation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using electronic health records from the UK Clinical Practice Research Datalink Aurum database, we included patients \u226540\u2005years old with moderate or severe COPD exacerbations. The outcome was fatal or non-fatal MACE (acute coronary syndrome, arrhythmia, heart failure or ischaemic stroke). Cause-specific hazard models were used to estimate the coefficient of predictors. Model performance was assessed by Nagelkerke's R\n                      <jats:sup>2<\/jats:sup>\n                      , Harrell's C statistic, calibration-in-the-large, calibration slope and decision curve analysis. Internal\u2013external cross validation was used to evaluate model performance across nine geographic regions. A risk score was derived from the original coefficients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 338\u2009981 patients were included. The overall 1-year cumulative incidence rate of MACE following COPD exacerbation was 5.04% (95% confidence interval 4.96\u20135.12%). Six predictors were retained: age, exacerbation severity, MACE history, modified Medical Research Council dyspnoea scale, hypertension and diabetes. In internal\u2013external cross validation, the pooled estimation for Nagelkerke's R\n                      <jats:sup>2<\/jats:sup>\n                      was 3.120% (2.945\u20133.295%) and Harrell's C statistic was 0.752 (0.746\u20130.759). Calibration-in-the-large was \u22120.006 (\u22120.008\u2013 \u22120.004) and the calibration slope was equal to 0.999 (0.977\u20131.020). These results suggest that the model has clinical utility, with higher net benefit than default strategies across the risk thresholds range from 2% to 18%. Model-driven risk stratification demonstrated significantly different cumulative incidence rates among these risk categories. Sensitivity analysis revealed that the CE-MACE model is generalisable to those patients with any history of COPD exacerbation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CE-MACE model highlights the burden of cardiovascular multimorbidity in patients with COPD. The model could help precisely identify those at high risk in clinical practice and promote integrated multidisciplinary healthcare for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.02555-2025","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:00:12Z","timestamp":1772726412000},"page":"2502555","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Developing and validating the CE-MACE model to predict 1-year major adverse cardiovascular events post-COPD exacerbation using routine healthcare data"],"prefix":"10.1183","volume":"68","author":[{"given":"Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-4751","authenticated-orcid":false,"given":"Anne E.","family":"Ioannides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Kallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K.","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026072302550521000_68.1.2502555.1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-2600(24)00339-4","article-title":"The global burden of COPD: epidemiology and effect of prevention strategies","volume":"13","author":"de Oca","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026072302550521000_68.1.2502555.2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report. 2026. Available from: http:\/\/goldcopd.org\/"},{"key":"2026072302550521000_68.1.2502555.3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-2600(22)00533-1","article-title":"Exacerbations in COPD: a personalised approach to care","volume":"11","author":"Jos\u00e9 Soler-Catalu\u00f1a","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026072302550521000_68.1.2502555.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2847"},{"key":"2026072302550521000_68.1.2502555.5","doi-asserted-by":"crossref","first-page":"17534666221113647","DOI":"10.1177\/17534666221113647","article-title":"Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"M\u00fcllerov\u00e1","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2026072302550521000_68.1.2502555.6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1164\/rccm.202307-1122OC","article-title":"Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation: a population-based study","volume":"209","author":"Graul","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072302550521000_68.1.2502555.7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033882"},{"key":"2026072302550521000_68.1.2502555.8","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.jacadv.2025.102172","article-title":"Risk of major adverse cardiovascular events during acute Streptococcus pneumoniae infection in COPD patients","volume":"4","author":"Riisberg","year":"2025","journal-title":"JACC Adv"},{"key":"2026072302550521000_68.1.2502555.9","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2147\/COPD.S529171","article-title":"Major adverse cardiovascular events and cause-specific mortality after hospitalisation in COPD","volume":"20","author":"Ioannides","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026072302550521000_68.1.2502555.10","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220615"},{"key":"2026072302550521000_68.1.2502555.11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-2600(24)00038-9","article-title":"MACE in COPD: addressing cardiopulmonary risk","volume":"12","author":"Hurst","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026072302550521000_68.1.2502555.12","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0050-2025"},{"key":"2026072302550521000_68.1.2502555.13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026072302550521000_68.1.2502555.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0442-4"},{"key":"2026072302550521000_68.1.2502555.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005540"},{"key":"2026072302550521000_68.1.2502555.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151357"},{"key":"2026072302550521000_68.1.2502555.17","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S117867"},{"key":"2026072302550521000_68.1.2502555.18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5"},{"key":"2026072302550521000_68.1.2502555.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017719"},{"key":"2026072302550521000_68.1.2502555.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441"},{"key":"2026072302550521000_68.1.2502555.21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/09622802231165001","article-title":"Imputation and missing indicators for handling missing data in the development and deployment of clinical prediction models: a simulation study","volume":"32","author":"Sisk","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"2026072302550521000_68.1.2502555.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-074819"},{"key":"2026072302550521000_68.1.2502555.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.08.038"},{"key":"2026072302550521000_68.1.2502555.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378"},{"key":"2026072302550521000_68.1.2502555.25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026072302550521000_68.1.2502555.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0938"},{"key":"2026072302550521000_68.1.2502555.27","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1093\/eurheartj\/ehae628","article-title":"The Global Working Group on Cardiopulmonary Risk in chronic obstructive pulmonary disease","volume":"45","author":"Gale","year":"2024","journal-title":"Eur Heart J"},{"key":"2026072302550521000_68.1.2502555.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"2026072302550521000_68.1.2502555.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099"},{"key":"2026072302550521000_68.1.2502555.30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"2026072302550521000_68.1.2502555.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02364-2022"},{"key":"2026072302550521000_68.1.2502555.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02905-y"},{"key":"2026072302550521000_68.1.2502555.33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chest.2025.09.133","article-title":"Cardiovascular events in COPD: complementary role of cardiac risk and coronary artery calcification","volume":"169","author":"de-Torres","year":"2026","journal-title":"Chest"},{"key":"2026072302550521000_68.1.2502555.34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/EDE.0000000000001349","article-title":"Accounting for repeat pregnancies in risk prediction models","volume":"32","author":"Grandi","year":"2021","journal-title":"Epidemiology"},{"key":"2026072302550521000_68.1.2502555.35","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf077"},{"key":"2026072302550521000_68.1.2502555.36","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41598-025-27988-6","article-title":"Plasma growth differentiation factor-15 is associated with cardiovascular events in patients hospitalized for acute exacerbation of COPD","volume":"16","author":"Sivapalan","year":"2026","journal-title":"Sci Rep"},{"key":"2026072302550521000_68.1.2502555.37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/jcm15010049","article-title":"COPD and cardiovascular diseases: biomarker-guided stratification and therapeutic perspectives","volume":"15","author":"Valizadeh","year":"2025","journal-title":"J Clin Med"},{"key":"2026072302550521000_68.1.2502555.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2212850"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02555-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:55:19Z","timestamp":1784800519000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02555-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/13993003.02555-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02555-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}